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Background: Human Immunodeficiency Virus Type I (HIV-1) infection is associated with a high incidence of B-cell
lymphomas. The role of HIV in these lymphomas is unclear and currently there are no valid in vivo models for
better understanding HIV-related lymphomagenesis. Transgenic (Tg) 26 mice have a 7.4-kb pNL4-3 HIV-1 provirus
lacking a 3.1-kb sequence encompassing parts of the gag-pol region. Approximately 15% of these HIV Tg mice
spontaneously develop lymphoma with hallmark pre-diagnostic markers including skin lesions, diffuse
lymphadenopathy and an increase in pro-inflammatory serum cytokines. Here we describe the phenotypic and
molecular characteristics of the B cell leukemia/lymphoma in the Tg mice.
Results: The transformed B cell population consists of CD19+pre-BCR+CD127+CD43+CD93+ precursor B cells. The
tumor cells are clonal and characterized by an increased expression of several cellular oncogenes. Expression of B
cell-stimulatory cytokines IL-1β, IL-6, IL-10, IL-12p40, IL-13 and TNFα and HIV proteins p17, gp120 and nef were
elevated in the Tg mice with lymphoma.
Conclusions: Increased expression of HIV proteins and the B-cell stimulatory factors is consistent with the
interpretation that one or more of these factors play a role in lymphoma development. The lymphomas share
many similarities with those occurring in HIV/AIDS+ patients and may provide a valuable model for understanding
AIDS-related lymphomagenesis and elucidating the role played by HIV-1.
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Human Immunodeficiency Virus Type I (HIV-1) infec-
tion is associated with an elevated incidence of B-cell
non-Hodgkin’s lymphoma (NHL) and in recent years
also with Hodgkin’s lymphoma [1]. NHL includes differ-
ent pathologic subtypes; the most common are diffuse
large B-cell lymphoma and Burkitt’s lymphoma [1].
Lymphoma risk is increased approximately 150- to 250-
fold among HIV-infected patients compared with the
general population [1-3]. HIV-associated lymphomas
(HAL) are aggressive and involve extranodal sites [1].
HAL development is frequently preceded by persistent
generalized lymphadenopathy, suggesting antigen-
induced chronic B cell stimulation and a likely patho-
genic link between B cell hyperplasia and AIDS-NHL
[4-6]. Chronic B cell activation may drive proliferation
of antigen-selected B cell clones that accumulate genetic* Correspondence: scurreli@ihv.umaryland.edu
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reproduction in any medium, provided the orlesions and ultimately undergo neoplastic transform-
ation. Indeed, elevated serum levels of several B cell
stimulatory factors, including cytokines [7] and other
soluble proteins [7-9], occur before the diagnosis of
AIDS-associated lymphoma. In addition, continued anti-
genic stimulation of B cells by HIV [10-12] or other
infectious agents such as Epstein-Barr virus [13] or
human herpesvirus 8 (HHV-8) [14] seems to be critical
for lymphomagenesis.
Different mouse lines transgenic for HIV-1 have been
generated [15-18] and have been useful for modeling
AIDS-like pathologies [19]. One of these, the HIV-1 Tg
mouse line Tg 26, has a pNL4-3 HIV-1 proviral trans-
gene lacking parts of the gag-pol region [20] and has
been extensively used to model HIV-induced pathologies
[20-23]. Here we report a phenotypic and molecular
characterization of B cell tumors that develop in Tg26
mice. Similar to human HAL, Tg lymphomas are pre-
ceded by diffuse lymphadenopathy and increased pro-
inflammatory serum cytokines. The transformed B cellLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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+CD93+ precursor B cells and are clonal.
Murine models for human AIDS-related B cell lymph-
omas have been lacking. Hence, Tg26 mice may repre-
sent an important tool for understanding the role of
HIV-1 in lymphomagenesis.
Results
HIV Tg mice developing lymphoma have abnormal
lymphoid phenotypes
HIV Tg26 heterozygous mice share a common pheno-
type characterized by cataracts, cutaneous papillomas
(Figure 1A, 1B) and renal disease [20-23]. The percent-
age of heterozygous Tg mice with skin lesions increased
with age and varied from 18% to 59%, as previously
reported [22]. By 8–12 months of age approximately
15% of the mice with cutaneous papillomas (15/100)
developed splenomegaly, lymphadenopathy and extra-
nodal involvement of liver, gastrointestinal tract and
central nervous system (Figure 1C, D). H&E staining
of lymphoid organs liver (Figure 1E), lymph node
(Figure 1F) and spleen (Figure 1H) showed all with
atypical lymphomatous infiltration. Spleen sections
(Figure 1G, H) showed a disorganized spleen architec-Figure 1 Abnormal lymphoid phenotype in HIV Tg mice. (A-B) Skin les
shows a papilloma (low power). C-F Multi-organ involvement by lymphom
(gross). (D) Spleen weight/total body weight ratio in HIV Tg mice compare
analyzed. The spleen weight/body weight ratios were approximately 23 tim
infiltration by lymphoma cells in the liver (H&E; x400); (F) Lymphomatous in
and HIV-Tg mouse spleen. (G) Normal splenic architecture in control mice
lymphoid infiltration and numerous hyperplastic megakaryocytes (H&E; x40
shows circulating lymphoblasts with scant basophilic cytoplasm, high nucle
chromatin, and inconspicuous nucleoli. Small cytoplasmic and nuclear vacuture with loss of germinal centers and atypical lymphoid
infiltration. Peripheral blood smears (Figure 1I) displayed
circulating lymphoblasts.
Expression of HIV mRNA and proteins in Tg mice with
splenomegaly
To measure HIV Tg expression, spleen and lymph node
sections from Tg26 mice at different stages of disease
were analyzed for HIV-1 unspliced (US), single spliced
(SS) and multiply spliced (MS) transcripts [24]. Viral
RNA was quantified in HIV Tg mice at different stages
of splenomegaly by semiquantitative real-time RT-PCR
and was expressed as fold increase relative to the levels
expressed in Tg26 mice with no signs of disease. Signs of
disease progression in Tg mice with skin papillomas
were defined based on clinical signs (e.g. abdominal en-
largement and ragged fur) and by analyses of T/B cell ra-
tios in peripheral blood (Table 1).
There were considerable differences in the levels of
HIV genes expressed in the spleen and the levels
expressed in lymph nodes from the same mouse
(Table 1). Minimal changes in HIV gene expression in
the spleen occurred with disease development (0.74
±0.23-fold increase in MS RNAs over controls, 1.26±1.6-ions in HIV-Tg mice. (A) Fungating lesions in the skin; (B) Histology
a in the HIV-Tg mice. (C) Hepatosplenomegaly and lymphadenopathy
d to control wild type FVB/N. 10 HIV Tg and 10 control animals were
es greater than that of wild type (WT) mice (p=0.0004). (E) Portal
filtration of the lymph node (H&E; x400). G-H Comparison of control
(H&E; x400); (H) Disorganized splenic architecture with atypical
0). (I) Wright-Giemsa staining of peripheral blood smears. The staining
i to cytoplasm ratio, round to irregular nuclei, slightly clumped
oles were occasionally seen.
Table 1 HIV gene expression in HIV Tg mice
SPLEEN LYMPH NODE LYMPH NODE/SPLEEN
Mouse number T/B ratio HIV genes T/B ratio HIV genes HIV genes
MS SS US MS SS US MS SS US
M5 23/65 - - - 86/12 - - - - - -
M15 25/74 0.56 0.26 0.78 nd 2.56 1.4 1.48 4.57 5.38 1.90
M22 5/69 0.18 0.0 0.45 70/30 0.87 6.28 1.24 4.83 6.28 2.76
M21 3/60 0.20 0.48 0.68 30/70 0.7 0.91 1.11 3.50 1.90 1.63
M7 4/96 2.11 2.7 0.62 25/75 1.62 3.46 5.00 0.77 1.28 8.06
M16 5/83 0.66 1.53 0.87 12/78 0.87 2.67 1.20 1.32 1.75 1.38
M20 2/58 0.04 0.1 0.09 1/92 18.9 20 5.55 ˃100 >100 61.67
M13 1/83 1.36 1.37 0.43 5/95 1.9 2.44 7.81 1.40 1.78 18.16
M2 4/86 0.37 0.8 2.36 11/84 0.17 1.13 1.29 0.46 1.41 0.55
M11 2/90 1.64 5.12 0.96 1/92 0.77 1.78 1.14 0.47 0.35 1.19
Viral RNA was quantified in HIV Tg mice at different stages of splenomegaly by semiquantitative real-time RT-PCR and was expressed as fold increase relative to
the levels expressed in Tg 26 mice with no signs of disease. The lefts column indicates the numbers assigned to the mice. Both spleen (on the left) and lymph
node (on the center) were analyzed for each mouse. The table shows T/B ratio and semiquantitative real-time RT-PCR of HIV MS (multiply spliced), SS (single
spliced) and US (unspliced) RNAs. The ratio of the RNA levels in the lymph node versus that in the spleen of the same mouse is shown on the extreme right.
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controls, respectively). In contrast, HIV gene expression
in lymph nodes, although still highly variable, was in-
creased relative to controls (2.87±1.8-fold increase in
MS RNAs over controls, 4.09±1.8-fold and 2.87±0.95-
fold increase in SS and US RNAs over controls,
respectively).
However in mice with T/B ratio of 25/75 and lower,
difference in viral RNA levels in spleen and in lymph
nodes from the same mouse was less evident. In particu-
lar, expression of HIV MS and SS RNAs in the lymph
node was reduced and nearly similar to the expression
level in spleen, while expression of US RNAs did not
correlate with T/B ratio (Table 1). This reduction in the
levels of HIV genes expressed in lymph nodes is prob-
ably due to B cell infiltration in the lymph node during
disease progression.
In support of viral RNA expression data, we
performed Western blots to measure HIV-1 gp120 pro-
tein in Tg mice at different stages of disease (Figure 2A,
B). Expression of gp120 was higher in lymph node ver-
sus spleen from the same mouse. To determine if HIV-1
genes are differentially expressed at the protein level in
Tg mice at different stages of lymphadenopathy, proteins
from splenocytes isolated from 3 WT, asymptomatic Tg
mice without skin lesions (Tg no S), Tg mice at early
stages of lymphadenopathy (Tg pre-L), and Tg mice at
late stages of lymphadenopathy (Tg L) were subjected to
SDS-PAGE and immunoblotting with anti-HIV anti-
bodies specific for p17 and nef (Figure 2C). We found
that Tg mice at late stages of lymphadenopathy express
elevated levels of HIV proteins known to interact with
B cells (p17, gp120, and nef) [10,25,26] compared to
asymptomatic Tg mice without skin lesions (Figure 2).Further, Tg mice at early stages of lymphadenopathy had
elevated levels of p17 and gp120 but not nef supporting
a possible role of p17 and gp120 in lymphomagenesis.
Elevated expression of pro-inflammatory cytokines in Tg
mice
Lymphoma in HIV+ patients is associated with immune
deregulation [9] and abnormal expression of certain cy-
tokines and chemokines [27,28] are considered bio-
markers for lymphoma development. To determine if
disease progression in HIV Tg mice is associated with a
similar cytokine signature, we measured cytokine levels
in the plasma of Tg mice at different stages of lymph-
adenopathy. Expression of IL-1β, IL-6, IL-10, IL-12p40,
IL-13, TNFα and chemokines MIP-1β MCP-1 and G-
CSF (Figure 3) by asymptomatic Tg no S was greater
than that of WT controls, although only for IL-12p40
(P=0.049), MIP-1β (P=0.009), and G-CSF (P=0.05) were
the changes significant. Differences were more evident,
however, in levels of IL-12p40 (P=0.002), IL-13 (P=0.008),
TNFα (P=0.019) and chemokines MIP-1β (P=0.006),
MCP-1 (P=0.002) (but not IL-1β, IL-6, IL-10 and
G-CSF) when comparing Tg pre-L to WT controls
(Figure 3). Similarly, IL-6 (P=0.0006), IL-10 (P=0.001),
IL-12p40 (P=0.03), TNFα (P≤0.002) and chemokines
MIP-1β (P<0.0001) and MCP-1 (P=0.002) (but not IL-
1β, IL-13 and G-CSF) were significantly elevated in Tg
mice at late stages of lymphadenopathy (Tg L) relative to
WT controls. Collectively the data show significant and
progressive increases in plasma IL-1β, IL-6, IL-10, IL-12
p40, IL-13 and TNFα during progression to splenomeg-
aly, suggesting that, as in HIV patients developing
lymphoma [27,28], these changes are prognostic for the
development of lymphadenopathy and splenomegaly in
Figure 2 HIV proteins expression in HIV Tg mice. (A) gp120 expression in HIV Tg mice. Protein lysates from mice spleen and lymph node
were separated by SDS-PAGE and analyzed by western blot using anti-gp120 antibody as described under “Experimental Procedures”. The mice
analyzed are indicated on the top of the figure: WT is the mouse control FVB/N, Tg is an HIV Tg mice without skin lesions, mice number 18, 21,
and 22 represent mice at the pre-lymphadenopathy stage while mice number 11, 20 and 35 represent mice at a late stage of lymphadenopathy.
The numbers in the right represent the protein molecular weight in KDa. (B) Histogram showing the fold changes in gp120 expression in the
lymph node versus the spleen from the same mouse. The relative intensity of gp120 was quantified by densitometry and normalized with the
beta actin. (C) Western blot for p17 and nef proteins expression in HIV Tg mice using anti-p17 antibody and HIV-1 Nef antiserum as described
under “Experimental Procedures”. The mice analyzed are indicated on the top of the figure: WT are mice wild type control FVB/N, Tg are HIV Tg
mice without skin lesions, Tg pre-L are mice at pre-lymphadenopathy stage and Tg-L are mice at the last stage of lymphadenopathy. The protein
molecular weights are represented in the right of the figure.
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of MIP-1β, MCP-1 and G-CSF; however, no association
of these chemokines with HIV-related lymphomas has
been reported.
Loss of peripheral B cell lineage and expansion of
precursor B cell populations in HIV Tg mice with
splenomegaly
To better characterize the splenomegaly, splenic B cell
populations from Tg mice at different stages of disease
progression were analyzed by flow cytometry (Figure 4).
Consistent with the splenomegaly, splenic B/T cell ratios
were increased in mice progressing toward splenomeg-
aly. We observed a loss of most of the peripheral B cell
lineage, including immature, mature, follicular, marginalzone B cells, plasma cells, and B1b cell population
(Figure 4). HIV Tg26 mice during the last stages of
splenomegaly had an expanded immature B cell popula-
tion consisting of CD19+B220+IgMlowIgD-CD21lowCD23-
CD138+CD5+ cell. Staining for precursor B cell markers
[29] revealed that the majority of B cell populations cir-
culating in peripheral blood as well in bone marrow and
spleen during the last stages of splenomegaly consisted
of B220+CD19+CD43+CD93+CD127+ precursor B cells
(Figure 4G, Additional file 1: Figure S1 and Additional
file 1: Table S1). These cells expressed mRNA for rag 1
and rag 2 enzymes (data not shown), suggesting that the
cell population invading the spleen derived from a B cell
precursor lying between the pro-B fraction B/C and the
pre-B fraction D based on the Hardy’s classification [29].
Figure 3 Cytokines and chemokines levels in the plasma of HIV Tg mice. Cytokine and chemokines production was compared among four
different groups: (i) FVB/N WT control (WT) (solid circles), (ii) asymptomatic Tg mice without skin lesions (Tg no S) (solid squares), (iii) Tg mice at
early stages of lymphadenopathy (pre-L) (solid triangles) and (iv) Tg mice at the late stage of lymphadenopathy (L) (inverted solid triangles).
Plasma samples from each group were collected and analyzed in triplicate. Bars denote the standard deviation. The p-values are represented as
lines in the figures and were calculated as unequal variance t-test between Tg no S, pre-L and L relative to the WT. The p values for anova are at
the bottom of each figure.
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cell markers CD34, c-kit and Sca-1 showed that while
c-kit expression remained mostly undetectable, Sca-1
and CD34 were expressed at high levels in mice with
splenomegaly (Figure 4H, I).
B cell clonality in HIV Tg mice with splenomegaly
In order to evaluate B cell clonality we used a PCR-
based method with primers specific for the D-J segment
of IgH [30]. DNA analysis of the spleen from HIV Tg
mice at different stage of disease progression shows that
both mice progressing to splenomegaly (Additional file
1: Figure S2A) and mice at the last stage of splenomeg-
aly (Additional file 1: Figure S2B) were polyclonal.
However while mice progressing to splenomegaly were
comparable to the WT control, some of the mice at thelast stage of splenomegaly showed preferential amplifica-
tion of one of the D-JH family of Ig variable genes, such
as D-JH3 for mice n.20, 28, 34, 37 and 11, or D-JH1 for
mouse n.16 (Additional file 1: Figure S2B). This suggests
the emergence of a clonal B cell population occurring
with advanced disease.
Oncogene expression in HIV Tg mice
We used real-time semiquantitative RT-PCR to measure
expression of different oncogenes associated with B cell
lymphomas [31-34] in Tg mice (Additional file 1: Table
S2). Based on oncogene expression patterns in the
spleen and the lymph node (Table 2), mice at different
stages of disease were categorized into three groups
(Additional file 1: Figure S3 and S4). Group A included
mice where oncogene expression was ≤ 5 times greater
Figure 4 Splenic peripheral B cell population in HIV Tg26 mice. Flow analysis was performed in splenocytes from wild type mouse FVBN
(WT), Tg26 without skin lesions (Tg no S), Tg26 at early stage of splenomegaly (Tg pre-L) and a Tg at advanced stage of splenomegaly (Tg L).
Splenic B cells comprised two major populations at side/forward scattered-high (SSC/FSChi), corresponding to non-activated and activated
populations (Figure 3 shows only the activated population). Starting from the left side, flow cytometry analysis of splenic B cell population in HIV
Tg26 mice displayed: (A) decrease of T versus B cell ratio, as shown by CD3 and CD19 staining; (B) decrease of immature (B220+IgD-IgM+) and
mature (B220+IgD+IgM-) B cells; (C) decrease in follicular (B220+CD21-CD23+) and marginal zone (B220+CD21+CD23-) B cells; (D) no change in
IgG1-expressing B cells (B220+IgG1+); (E) reduction in plasma cells (CD19+CD138+); (F) decrease in B1B cells (B220+CD5+); (G) increase of
precursors B cells (B220+CD43+CD93+); (H) increase of B220+Sca+ B cells; undetectable c-kit and (I) increase of B220+CD34+ B cells.
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tween a >5 to ≤ 10 fold increase in oncogene expression
compared to that of controls. For group C, the fold
increase was > 10. Small changes in the expression of
multiple oncogenes were observed in group A, while
mice in group B and to a greater extent in group C, in
addition to variable expression of multiple oncogenes,
had a dominant oncogene that was highly expressed,
suggesting that by this stage of disease genetic changes
had probably occurred. Of note, data with the spleen
(Additional file 1: Figure S3) are in agreement with the
clonality assay shown in Additional file 1: Figure S2. In-
deed in mouse n.11 from group B and in mice n.28 and
n.16 from group C with a greater than 10 fold increase
in relative expression of an oncogene, there was also
preferential amplification of one of the D-JH segments,
suggesting a shift in these mice of B cell populations to-
wards oligoclonality.
Although there was no consistent elevation of expres-
sion of specific oncogenes, different oncogenes were
upregulated in different mice progressing to splenomeg-
aly. Among the analyzed oncogenes bcl6, syk, k-ras, c-
rel, c-abl and cyclin D1 were variably increased, while
bcl2 and bcl3 did not change greatly (Table 2). The aber-
rant expression of oncogenes in spleen and lymph node
was often correlated with T/B cell ratios, both of which
were related to disease progression. When oncogenes
expressed in the spleen were compared with oncogenesexpressed in the lymph node from the same mouse,
common oncogenes were increased in mice n. 16, 28,
11, 22, 7 and 25 (Table 2). However, oncogenes that
were overexpressed in spleen and lymph node were not
the same in the majority of the mice analyzed,
suggesting that stochastic events or different micro-
environmental stimuli modulate oncogene expression in
the two tissues.
B cells from HIV Tg mice with splenomegaly are
tumorigenic
Splenic B cells were isolated from a mouse at the last
stage of splenomegaly and lymphadenopathy (mouse
n.28 in Table 2). The CD3- population from the mouse
splenocytes was further separated into four fractions
based on the B cell markers B220+, CD19+, CD93+ and
CD117+. 106 cells from each purified B cell population
were injected intraperitoneal into NOD/SCID mice.
Of the mice injected with selected B cell populations,
40% of B220+ and CD19+ injected mice developed
lymphoma, but only 20% of those injected with CD93+
cells developed lymphoma and all of those injected with
CD117+ cells or CD3+ control cells remained healthy
(Additional file 1: Figure S5). FACS analysis demon-
strated infiltration of CD19+ cells into lymphoid organs
(Additional file 1: Figure S6). Phenotypically, the tumors
from the injected mice consisted of one or two main
populations at SSC/FSChi (Figure 5A and Additional
Table 2 Oncogenes expression in HIV Tg mice
T/B BCL2 BCL3 BCL6 C-REL MUM1 C-MYC CYC D1 SYK K-RAS ABL
M4 S 77(2/58) 0.09 2.51 8.75 0.14 0.02 2.25 14.13 0 0.79 1.95
L
M9 S nd 1.00 0.94 1.32 0.39 0.69 0.58 0.81 nd 1.59 nd
L
M24 S nd 3.7 2.55 4.9 6.15 0.71 1.99 3.65 2.12 1.98 nd
L nd 2.68 1.00 0.42 2.91 0.35 0.04 0.54 0.33 1.63 1.07
M25 S 32(47/54) 4.99 4.98 8.88 4.42 0.75 0.89 2.85 0.60 0.80 0.76
L nd 3.13 0.06 1.00 7.14 0.64 0.64 0.26 3.88 3.16 1.48
M1 S 26(31/58) 2.77 1.14 1.58 1.59 1.14 0.23 1.68 0.02 1.44 1.24
L 71(77/23) 0.9 2.5 1.06 0.78 3.49 0.43 0.59 2.56 0.63 nd
M3 S 25(16/77) 2.52 3.67 2.38 6.62 0.67 3.6 1.88 7.7 2.31 nd
L nd
M15 S 23(25/74) 0.28 0.61 1.02 0.12 0.19 0.93 0.70 1.56 2.31 1.59
L nd 2.93 0.32 1.80 6.95 0.4 0.77 0.28 1.98 2.83 1.12
M22 S 61(5/69) 0.32 1.39 0.71 0.27 0.95 0.32 0.88 1.34 0.18 5.91
L 93(70/30) 3.33 0.68 0.19 3.33 0.94 0.52 0.25 0.87 5.33 8.39
M21 S 60(3/60) 1.98 0.96 2.64 1.03 2.56 1.92 3.92 2.46 0.44 1.91
L 80(30/70) 0.92 0.79 0.19 2.45 1.28 0.07 0.65 3.66 3.93 2.25
M2 S 20(4//86) 0.46 0.20 1.09 0.07 4.21 2.52 8.75 0.06 2.29 2.67
L 25(25/75) 0.58 0.4 1.12 1.07 1.7 3.23 0.47 3.18 1.5 5.01
M7 S 80(4/96) 0.21 0.53 0.22 0.46 5.1 0.60 0.41 2.32 2.98 2.27
L 54(27/75) 0.43 0.39 0.41 2.32 5.78 2.56 0.8 8.75 9.39 9.19
M11 S 85(2/90) 1.74 3.27 5.17 8.23 7.02 2.74 1.23 8.69 2.89 3.84
L 88(1/92) 0.04 2.69 0.2 2.83 5.6 0.78 0.13 4.6 1.89 3.41
M13 S 40(2/77) 0.44 1.57 1.94 2.69 2.99 1.78 0.61 3.45 2.77 0.17
L 40(5/95) 2.29 0.70 0.24 9.19 4.74 0.30 0.56 21.45 8.96 6.4
M16 S 35(5/83) 3.50 0.80 3.68 13.48 2.07 1.81 5.13 8.4 19.45 nd
L 53(15/85) 0.73 1.49 0.28 4.52 0.95 3.61 4.91 2.53 16.76 8.23
M20 S 77(2/58) 0.21 0.86 0.23 0.23 0.46 0.68 0.72 1.41 0.25 0.93
L 75(1/99) 0.06 0.22 0.07 0.89 2.7 0.96 0.15 4.64 2.01 5.31
M28 S 55(2/90) 0.38 0.72 0.69 1.03 5.96 15.38 0.41 1.51 6.28 0.11
L nd 0.42 0.21 0.18 0.55 nd 5.54 0.28 1.98 2.1 3.35
Total RNA was isolated from spleen and lymph node of mice at different stage of splenomegaly and was analyzed using primers specific for oncogenes associated
to lymphoma (Additional file 1: Table S2) by SYBR Green semiquantitative real-time RT-PCR as described in material and methods. The fold change in each
oncogene mRNA compared to the wild type FVBN control is shown relative to the change in the expression of β-actin that was measured as an internal control.
The expression of each oncogene in the wild type FVBN control was set to 1. Each mouse is designated with M followed by a number (first column). For each
mouse the first line represents the spleen (S), second line represents lymph nodes (L).T/B ratio is indicated in parenthesis and is calculated on total activated cells.
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CD19+, as well 70% of the total CD3- injected mice
developed tumors consisting of one population of non-
activated and one population of activated B cells, tumors
in CD93+ injected mice and in 30% of the total CD3-
injected mice included only one activated population. The
activated tumorigenic population, commonly present in all
tumors, was B220+/−CD19+CD43+CD93+pre-BCR+CD127
+IgM+CD21+/−CD5+/−CD138+Sca1+ and CD34-, whereas
the non-activated B cell population was B220+ CD19+CD43+CD93+pre-BCR+CD127+IgM+CD21+CD5+CD138-
Sca1+ and CD34+. The B cell marker B220 was
expressed only in the non-activated B cell population
from all tumors, with the exception of the those gen-
erated from CD19+ injected mice, which were consist-
ently B220+ (Figure 5A and Additional file 1: Figure
S7). B cell markers CD21, CD5, CD138 and CD34
were variably expressed in the tumorigenic population
and probably simply reflected the activation stage of
the cells.
Figure 5 Tumors characterization. (A) Phenotypic analysis of extranodal tumors developed in NOD/SCID mice injected with splenocytes from
HIV Tg mouse #28. Flow analysis was performed in tumors from mice from groups injected with CD19+, B220+, CD93+, and the control CD3-.
Mice shown are representative from each group. Tumors were analyzed for the following cell markers consisting in: CD3, CD19, CD43, CD93,
B220, IgM, CD21, CD5, pre-BCR, Sca1, CD127, CD138, and CD34. “g1”and “g2” indicate the not activated and activated gates, respectively. “+”, “++”,
“+++” indicate peak fluorescence intensity one, two or three logs higher than isotype control, respectively; “-” indicates no change in peak
fluorescence intensity compared to isotype control; “+/−” indicates peak fluorescence intensity less than one log higher than isotype control.
Flow histograms of extranodal tumors are shown in Additional 1: Figure S7. (B) Analysis of D-J rearrangement of the IgH gene. Genomic DNAs
from extranodal tumors developed in NOD/SCID injected with B220+, CD19+, CD93+ and CD3- splenocytes purified from HIV Tg mouse n.28 were
analyzed for D-J rearrangement of the IgH gene. Splenocytes from a wild type (WT) FVBN mouse were used as a control polyclonal B cells show
four bands corresponding to D-JH1, D-JH2, D-JH3 and D-JH4, indicating that these four segments were rearranged, while tumors were
monoclonal. The repertoire of Ig genes utilized in the monoclonal tumors indicated a preferential usage of the D-JH3 family of Ig H variable
genes. (C) Molecular analysis of oncogenes expressed in extranodal tumors developed in NOD/SCID injected with B220+, CD19+, CD93+ and CD3-
splenocytes purified from HIV Tg mouse n.28. A single mouse representative for each group of mice injected is shown. Oncogenes analysis was
performed by SYBR Green semiquantitative real-time RT-PCR as described in material and methods.
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the secondary tumors reflect a difference in the clonal
origin of the tumors, we evaluated B cell clonality.
Whereas splenocytes from mouse n.28, from whom the
tumorigenic B cells were derived, were polyclonal
(Additional file 1: Figure S2B), the tumors that devel-
oped in recipient mice displayed a monoclonal IgHrearrangement (Figure 5B). These results suggests that
only one of the multiple B cell clones detected by
IgH rearrangements in the HIV Tg mouse n.28 pro-
duced the malignant B clones in all secondary tu-
mors, while other B cell clones from this mouse,
although immortalized were not (or at least were less)
malignant.
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Tg mouse n.28 (Table 2) with the oncogenes expressed
in the tumors developed in the NOD/SCID mice
injected with B cells fractions from mouse n.28
(Figure 5C). Molecular analysis of the oncogenes
expressed in the spleen from mouse n.28 showed in-
creased expression of c-myc (15.38 ± 0.96), k-ras (6.28 ±
0.56) and mum1 (2.94 ± 0.1). In contrast, there was no
significant increase in the expression of c-rel, syk, bcl2,
bcl3 and bcl6. RNA from the tumors that developed in
mice injected with B cell fractions B220+, CD19+, CD93+
and CD3- controls expressed, similar to mouse n.28, ele-
vated levels of c-myc, k-ras and mum1 oncogenes with a
fold increase comparable to mouse n.28 (Figure 5C).
These results demonstrate that the tumorigenic B cell
population derived from mouse n.28 preserved its mo-
lecular signature in the recipient NOD/SCID mice and
suggest a role for c-myc in lymphomagenesis.
HIV Tg mice developing lymphoma do not express v-abl
A similar pattern of pre-B cell transformation occurs fol-
lowing infection with Abelson murine leukemia virus
(Ab-MLV) which encodes the v-Abl tyrosine kinase gene
[35,36]. In order to exclude the possibility that the pre-B
cell transformation in HIV Tg mice was due to infection
with Ab-MLV, we tested DNA and cDNA from the
spleen of mice with lymphoma for the presence of v-abl.
Four different sets of primers were tested since v-Abl is
expressed in different forms [35]. We used primers
124F/R, 310F/R, 382F/R and 4664F/R (Additional file 1:
Table S3) that target diverse regions of the viral protein
but do not recognize c-abl. The macrophage cell line
Raw 264.7 cDNA [37] was the positive control. None of
the tested primers detected v-abl mRNA (data not
shown). However, expression of the cellular oncogene
c-abl was variably modulated in HIV Tg mice with
lymphoma (Table 2).
Discussion
In this report we characterize the phenotypic and mo-
lecular features of B cell leukemia/lymphomas that
develop in Tg26 mice HIV-1 Tg mice. About 15% of Tg
mice develop B cell lymphomas with a constellation of
pre-diagnostic markers similar to those of B cell lymph-
oma in HIV patients, thus providing the first animal
model for elucidating the mechanisms by which HIV in-
fection leads to AIDS-related B cell lymphomas.
The lymphomagenic role of HIV-1 is not well under-
stood, although HIV-induced chronic B cell stimulation
appears to be critical [4-6]. Numerous studies suggest
roles for several HIV proteins, including Tat [11], Nef
[26], Env gp120 [10], and Gag p17 [25], in mediating B
cell hyper-proliferation [4-6] that precedes lymphoma in
HIV patients. HIV-1 induces B cell-stimulatory cytokinesincluding IL-6 and IL-10, which are pre-diagnostic for
HAL [7,27,28]. Similarly to the clinical data, Tg26 mice
with leukemia/lymphoma displayed: (i) splenomegaly,
lymphadenopathy and extra nodal enlargements in the
liver and the gastrointestinal tract (Figure 1); (ii) in-
creased lymph node expression of HIV-1 genes (Table 1),
increased expression of HIV proteins p17, gp120 and nef
in mice developing lymphoma (Figure 2); and (iii) sig-
nificant increases in serum cytokines including IL-6, IL-
10, TNF-α, IL-12 and IL-13 (Figure 3). HIV-1 structural
proteins gp120 and p17 persist in patients under high active
antiretroviral therapy [38], and the increased expression of
p17, gp120 and nef in Tg 26 mice developing lymphoma
suggest a lymphomagenic role of these proteins.
Loss of peripheral B cell subpopulations and infiltra-
tion of lymphoid organs by polyclonal B cells was a hall-
mark of HIV-1 Tg mice progressing to lymphoma. The
infiltrating B cell population retained a phenotype with
specific markers of precursor B cells (B220+CD19+CD43
+CD93+CD138+CD127+) [29] and expressed markers of
immature B cells (IgMlowIgD-CD21lowCD23-) [39] and
common lymphoid precursors (Sca1+c-Kit-CD34+) [40]
(Figure 4 and Additional file 1: Figure S1 and Additional
file 1: Table S1).
B220+, CD19+ and CD93+, but not c-kit+ splenocytes
isolated from an HIV Tg mouse in the last stage of
splenomegaly and lymphadenopathy induced tumors in
NOD/SCID mice. The tumorigenic pre-B cell population
was phenotypically similar to splenocytes from HIV Tg
mice with splenomegaly and consisted of B220+/−CD19
+CD43+CD93+pre-BCR+CD127+CD138+IgM+CD21
+/−CD5+/−Sca1+ and CD34+/−, with B cell markers B220,
CD21, CD5, CD138 and CD34 variably expressed and
probably linked to the activation stage of the cells
(Figure 5A and Additional file 1: Figure S7).
Transplant tumors were monoclonal (Figure 5B), in
contrast to primary tumors, which were polyclonal
(Additional file 1: Figure S2). Therefore we assume that
both lymphoproliferation and ultimately full neoplastic
transformation occur in B cells from HIV-1 Tg mice and
that the malignant lymphomas arise from among the
multiple B cell clones detected by PCR clonality assays.
The presence of pre-B cells in the blood and bone mar-
row of Tg mice developing lymphoma and infiltrating
the lymphoma itself define this malignancy as precursor
B cell leukemia/lymphoma.
We speculate that lymphomagenesis in Tg26 mice is
due to a paracrine effect of viral or virally induced cellu-
lar proteins acting on a stem-like hematopoietic cell be-
longing to a common lymphoid precursor or a pre-B
cell. In this scenario HIV would perturb B cell differenti-
ation, with consequent immortalization and transform-
ation of cells at the B cell precursor stage. Indeed, the
regulation of proliferation of precursor B cells is an
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is particularly prone to transformation. The differenti-
ation of pre-B cells is dependent upon the regulatory
interplay between IL-7 receptor and pre-BCR signaling
[41,42], as well the activity of B cell transcription factors
[43]. Active pre-BCR induces cell division, recombin-
ation of the immunoglobulin light chain and differenti-
ation of pre-B cells in immature B cells expressing
BCR [29]. However, defects in pre-BCR assembly and
signaling may interfere with B cell development or may
cause uncontrolled proliferation and genomic instability,
resulting in immunodeficiency or tumor development. It
is possible that one or more HIV proteins interfere with
differentiation of pre-B cells and delineation of the early
stages of B cell development in the Tg26 mice help es-
tablish a role for HIV in lymphoma development. Never-
theless these studies will need to exclude a role in
lymphomagenesis for viral proteins expressed within the
B cell population of the Tg model, suggesting the need
for an updated mouse model expressing the Tg only in
naturally HIV permissive cells.
Deregulated expression of one or more cellular onco-
genes is usually associated with cancer, including B cell
lymphomas [44,45] and leukemia [46]. ARL are charac-
terized by the presence of recurrent oncogene transloca-
tions [32,33], or by inactivating mutations and deletions
of the p53 tumor suppressor gene [47]. Molecular
analysis of oncogene expression in Tg26 mice shows an
increased expression of multiple oncogenes with the
dominant expression of single oncogenes in mice prog-
ressing to lymphoma. Oncogenes bcl6, syk, k-ras, c-myc
and cyclin D1 were variably increased, while bcl2 and
bcl3 did not change considerably. The aberrant expres-
sion of oncogenes in tg mice was often correlated with
T/B cell ratios, both of which were related to disease
progression.
Early studies of the HIV Tg26 line indicated that the
transgene is integrated in chromosome 8 in multiple
copies [20]. Analysis of the integration sites will obvi-
ously be important for understanding whether and how
the transgene may be causing genome instability com-
pared to the WT mouse. These studies are planned for
the near future.
Another potential role of HIV in lymphoma develop-
ment is HIV-associated immunosuppression [48]. Loss of
immune control can enable reactivation of latent onco-
genic viruses. Indeed HIV-associated lymphomas are often
positive for oncogenic EBV [13] or HHV-8 [14] infection,
both of which have direct roles in lymphoma development.
The possibility that HIV-1 Tg mice develop deficiencies in
immune cells that target tumors has yet to be investigated.
HIV Tg mice were negative for Abelson murine leukemia
virus; however, the transgene might be activating a murine
oncovirus [49] that could contribute to lymphoma.Conclusions
HIV Tg26 lymphomas bear many similarities to that of
lymphomas occurring in HIV+ patients. Currently there are
no murine models available for HIV-associated B cell
lymphoma. The HIV Tg26 mouse model allows for the
characterization of different stages of disease progression,
providing a potentially valuable model for lymphomagenesis
in HIV disease and for identifying potential roles of HIV-1
in B cell transformation in infected people.
Methods
Tg mice and generation of the HIV Tg mice colony
developing lymphoma
The transgenic mouse line TgN (pNL43d14)26Lab
(Tg26), was described previously [20]. The transgene
contains a 3 kb deletion spanning gag and pol genes.
Heterozygous mice were used for these studies since
homozygotes rarely survive to weaning [22]. The colony
developing lymphoma was generated by cross-breeding
heterozygous Tg26 mice with skin lesions.
Total RNA purification and real time RT-PCR
Total RNA was purified from lymphoid organs of mice.
Harvested tissues were preserved in RNAlater (Qiagen),
homogenized and total RNA purified using TRIzol
(Invitrogen, Carlsbad, CA) and QIAamp Rneasy Mini
Kit (Qiagen, Valencia, CA), and DNase I-digested
(Invitrogen). cDNA synthesis was performed using
iScript™ cDNA Synthesis Kit (Bio-Rad). Semiquantitative
real-time RT-PCR was performed using iQ™ SYBR®
Green Supermix Kit (Bio-Rad) with an ABI sequence de-
tection system (ABI PRISM 5700). All reactions were in
triplicate. Semiquantitative RT-PCR was performed to
detect expression of HIV mRNAs [50] and cellular onco-
gene mRNAs (Additional file 1: Table S2).
Western blot
Lymphoid organs from Tg mice were homogenized in
Ripa buffer containing a protease inhibitor mixture
(Sigma-Aldrich). Proteins (30 μg) were electrophoresed
(12% SDS-polyacrylamide), transferred to a PVDF mem-
brane (Bio-Rad), probed with anti-HIV-1 gp120 (Aalto Bio
Reagents Ltd., Ireland), anti-HIV-1 p17 (Abnova), HIV-1
Nef Antiserum (NIH AIDS Research and Reference Re-
agent Program), anti-beta actin (Cell Signaling) and anti-
mouse serum albumin (Abcam), incubated with respective
HRP-conjugated secondary antibodies (Santa Cruz, Inc.,
CA), developed using an ECL chemiluminescent substrate
kit (Invitrogen) and exposed to Kodak X-ray film.
Histological analysis
Mice were anesthetized with metofane and tissues fixed
overnight in 4% paraformaldehyde. Sections of paraffin-
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stained with hematoxylin and eosin (H&E).Adoptive transfer
Splenocytes from a mouse with advanced spontaneous
lymphoma were isolated with a tissue grinder (VWR Inter-
national). CD3+ cells and CD3- cells were separated using
MACS system (Miltenyi Biotec); next CD19+, B220+ and
CD117+ cells were isolated with magnetic bead separation.
Purity of B cell populations was evaluated by flow cytome-
try. One million CD3+, CD3-, CD19+, B220+ and CD117+
cells were injected I.P. in NOD/SCID mice. Derived tu-
mors were dissociated to single cells and analyzed for ex-
pression of lymphoid markers. All animal experiments
were approved by the IACUC at UMAB.Flow cytometry
Single cell suspensions were analyzed by flow cytometry.
The following antibodies were used (from eBioscience
and BD): antibody to B220 (anti-B220; RA3-6B2), anti-
CD3ε (17A2), anti-CD4 (GK1.5), anti-CD8a (53–6.7),
anti-CD11b (anti-Mac1; M1/70), anti-CD14 (Sa2-8),
anti-CD19 (1D3), anti-CD20 (AISB12), anti-CD22 (2D6),
anti-CD34 (RAM34), anti-CD27 (LG.7F9), anti-CD43
(eBioR2/60), anti-CD93 (AA4.1), anti-CD117 (anti-c-Kit;
2B8), anti-CD184 (anti-CXCR4; 2B11), anti-IgD (11-
26c), anti-IgG1 (A85-1), anti-IgM (II/41), anti-Sca1
(anti-Ly6A/E), anti-pre-BCR (SL-156) and anti CD127
(A7R34). Samples were acquired and analyzed with a
FACSCalibur (Becton Dickinson) and FlowJo software
(Tree Star, Ashland, OR), respectively.Immunoglobulin gene rearrangement
Ig gene rearrangements for clonal B-cell determination
of mouse tumors were detected by PCR using 0.1 mg of
DNA extracted from spleens of asymptomatic Tg26, and
transgenic mouse tumors using the DNeasy Tissue kit
(Qiagen). Primers for immunoglobulin D-Jβ gene
rearrangements of the IgH gene were previously de-
scribed [30]. Amplified DNA products were loaded on
6% TBE-urea gel, electrophoresed, and stained with eth-
idium bromide.Cytokine assays
Peripheral blood was collected from the eye, and plasma
was separated using plasma separators (BD Microtainer).
Plasma cytokines were determined using Bio-Plex Pro
assay cytokine kits (Biorad) following the manufacturer’s
instruction. Data from the reaction were acquired using
a Luminex-based reader (Biorad).Statistical analysis
Analyses were performed using GraphPad Prism v 5.0.
For categorical independent variables, differences be-
tween groups were assessed by using Student t test.Additional file
Additional file 1: Figure 1S. Splenic peripheral B cell population in
HIV Tg mice. Splenic peripheral B cell population in four HIV Tg mice in
advanced stage of splenomegaly. Flow cytometry analysis displayed: (A)
two major populations at SSC/FSChi; (B) increase of CD19+ B cells; (C)
increase of precursors B cells (B220+CD43+CD93+). Figure 2S. Analysis of
D-J rearrangement of the IgH gene. Genomic DNAs from splenocytes
isolated from HIV Tg mice progressing to splenomegaly (A) or at the last
stage of splenomegaly (B) were analyzed for D-J rearrangement of the
IgH gene. Splenocytes from a wild type FVBN mouse were used as a
control for polyclonal B cells. Four bands corresponding to D-JH1, D-JH2,
D-JH3 and D-JH4 were observed in the polyclonal B cells control. Figure
3S. Oncogenes expressed in the spleen of HIV tg mice. Total RNA was
isolated from spleen of mice at different stage of splenomegaly and was
analyzed using primers specific for oncogenes associated to lymphoma
(Additional 1: Table S3) by SYBR Green semiquantitative real-time RT-PCR
as described in material and methods. The fold change in each
oncogene mRNA compared to the wild type FVBN control is shown
relative to the change in the expression of β-actin that was measured as
an internal control. The expression of each oncogene in the wild type
FVBN control was set to 1. Each mouse is designated with M followed by
a number indicating the percentage of total activated cells and the T/B
ratio in parenthesis. Mouse number and T/B ratio are showed at the top
of each graphic. Oncogenes are indicated with letters a-j where (a) bcl2,
(b) bcl3, (c) bcl6, (d) c-rel, (e) mum1, (f) c-myc, (g) cyclin D1, (h) syk, (i) k-
ras, and (j) abl. Figure 4S. Oncogenes expressed in the lymph node of
HIV tg mice. Total RNA was isolated from lymph node of mice at
different stage of splenomegaly and was analyzed using primers specific
for oncogenes associated to lymphoma (Additional 1: Table S2) by SYBR
Green semiquantitative real-time RT-PCR as described in material and
methods. The results analysis in the lymph nodes are represented similar
to the results of oncogene analysis in the spleen shown in Additional 1:
Figure S3. Figure 5S. Percentage of mice that developed lymphoma. Six
groups of NOD/SCID mice where collected for the tumorigenic
experiment. Each group consisting of six mice was injected
intraperitoneal with 106 B220+, CD19+, CD93+ and CD117+ splenocytes.
Mice injected with CD3- and CD3+ splenocytes where used as positive
and negative control, respectively. At 6 weeks after injection all CD3-
injected mice become visibly ill, while all the CD3+ injected control mice
remained healthy. As with HIV Tg mice, signs of disease included
splenomegaly, lymphadenopathy and extra nodal enlargements in the
liver and the gastrointestinal tract. Figure 6S. Infiltration of tumorigenic
cells in lymphoid organs of NOD/SCID mice. Infiltration of CD19+ cells in
lymphoid organs of NOD/SCID mice injected with splenocytes from HIV
Tg mouse #28. Liver, lymph node, spleen and thymus were removed
from NOD/SCID mice and single cells from each organ were stained and
analyzed for CD19 and CD3 markers. Each organ contained two major
populations at SSC/FSChi, corresponding to non-activated and activated
populations (left panel). Flow cytometry analysis displayed CD19+ cells in
the activated population of all organs analyzed (right dot plot). The dot
plots shown are from one mouse and are representative of results from
four different mice. Figure 7S. Phenotypic characterization of tumors.
Flow analysis was performed in tumors from mice from groups injected
with CD19+, B220+, CD93+, 30% of the control CD3-, and 70% of the
control CD3-. Mice shown in figure are representative from each group.
Tumors were analyzed for the following cell markers consisting in: CD3,
CD19, CD43, CD93, B220, IgM, CD21, CD5, pre-BCR, Sca1, CD127, CD138,
and CD34. “g1”and “g2” indicate the not activated and activated gates,
respectively. Table S1. T/B cell ratio and precursors B cell population in
HIV Tg mice. Flow analysis was performed in blood, spleen and bone
marrow from wild type mouse FVBN (WT), Tg without skin lesions (TG),
Tg at early stage of splenomegaly (pre-L) and a Tg at advanced stage of
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and CD127 were reported as percentage of positive cells. A
representative of four different WT, TG, pre-L and L mice is shown.
Table S2. List of oncogenes and respective primers analyzed in this
study. Additional 1: Table S3. Oligonucleotide primers for detecting v-abl
from A-MuLV genome [GenBank accession AF033812].
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